NCT05810116View on ClinicalTrials.gov

Effectiveness of PEA Compared to Placebo on Acute Menstrual Pain

PHASE4CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

May 19, 2023

Primary Completion Date

December 20, 2023

Study Completion Date

December 20, 2023

Conditions
Menstrual Pain
Interventions
DRUG

Levagen+

Daily dose of 1-2 capsules (1 capsule containing 350mg Levagen+ equivalent to 300mg PEA)

DRUG

Microcrystalline cellulose

Daily dose of 1-2 capsules (1 capsule containing 350mg)

Trial Locations (1)

4006

RDC Clinical Pty Ltd, New Farm

All Listed Sponsors
lead

RDC Clinical Pty Ltd

INDUSTRY

NCT05810116 - Effectiveness of PEA Compared to Placebo on Acute Menstrual Pain | Biotech Hunter | Biotech Hunter